Synta Announces Encouraging Results of Ganetespib GALAXY-1 Trial at ECC 2013

Synta Pharmaceuticals

today announced presentation of results from the GALAXY-1 trial, a global, randomized, multi-center Phase 2b/3 study designed to identify the patients with advanced non-small cell lung adenocarcinoma most likely to benefit from second-line treatment with the Company's lead drug candidate, the Hsp90 inhibitor ganetespib. The results, from a planned interim analysis conducted in May, will be presented at the 2013 ECCO/ESMO/ESTRO conference and include a review of interim findings previously presented at ASCO 2013 as well as additional results for two of the study's prespecified primary patient populations. “We are encouraged by the improvements in PFS and OS in patients treated with ganetespib in the GALAXY-1 study,” said Dr. Vojo Vukovic,